401 related articles for article (PubMed ID: 21541671)
1. A prospective survey of Aspergillus spp. in respiratory tract samples: prevalence, clinical impact and antifungal susceptibility.
Mortensen KL; Johansen HK; Fuursted K; Knudsen JD; Gahrn-Hansen B; Jensen RH; Howard SJ; Arendrup MC
Eur J Clin Microbiol Infect Dis; 2011 Nov; 30(11):1355-63. PubMed ID: 21541671
[TBL] [Abstract][Full Text] [Related]
2. Susceptibility of fungi isolated from the respiratory tract of falcons to amphotericin B, itraconazole and voriconazole.
Silvanose CD; Bailey TA; Di Somma A
Vet Rec; 2006 Aug; 159(9):282-4. PubMed ID: 16946311
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the Sensititre YeastOne and CLSI M38-A2 Microdilution Methods in Determining the Activity of Amphotericin B, Itraconazole, Voriconazole, and Posaconazole against Aspergillus Species.
Wang HC; Hsieh MI; Choi PC; Wu CJ
J Clin Microbiol; 2018 Oct; 56(10):. PubMed ID: 30093391
[TBL] [Abstract][Full Text] [Related]
4. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592).
Manavathu EK; Cutright JL; Loebenberg D; Chandrasekar PH
J Antimicrob Chemother; 2000 Aug; 46(2):229-34. PubMed ID: 10933645
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the activities of amphotericin B, itraconazole, and voriconazole against clinical and environmental isolates of Aspergillus species.
Misra R; Malik A; Singhal S
Indian J Pathol Microbiol; 2011; 54(1):112-6. PubMed ID: 21393890
[TBL] [Abstract][Full Text] [Related]
6. In vitro activities of three licensed antifungal agents against spanish clinical isolates of Aspergillus spp.
Gomez-Lopez A; Garcia-Effron G; Mellado E; Monzon A; Rodriguez-Tudela JL; Cuenca-Estrella M
Antimicrob Agents Chemother; 2003 Oct; 47(10):3085-8. PubMed ID: 14506013
[TBL] [Abstract][Full Text] [Related]
7. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.
Pfaller MA; Messer SA; Hollis RJ; Jones RN;
Antimicrob Agents Chemother; 2002 Apr; 46(4):1032-7. PubMed ID: 11897586
[TBL] [Abstract][Full Text] [Related]
8. Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain.
Mortensen KL; Mellado E; Lass-Flörl C; Rodriguez-Tudela JL; Johansen HK; Arendrup MC
Antimicrob Agents Chemother; 2010 Nov; 54(11):4545-9. PubMed ID: 20805399
[TBL] [Abstract][Full Text] [Related]
9. A prospective survey of Aspergillus spp. in respiratory tract samples: Species identification and susceptibility patterns.
Castro C; Galán-Sanchez F; Linares MJ; Tejero R; Ruiz M; Serrano ML; Rodríguez-Iglesias M; Martín-Mazuelos E;
Med Mycol; 2019 Jun; 57(4):412-420. PubMed ID: 30289467
[TBL] [Abstract][Full Text] [Related]
10. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole.
Sutton DA; Sanche SE; Revankar SG; Fothergill AW; Rinaldi MG
J Clin Microbiol; 1999 Jul; 37(7):2343-5. PubMed ID: 10364610
[TBL] [Abstract][Full Text] [Related]
11. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole.
Kaya AD; Kiraz N
Mycoses; 2007 Nov; 50(6):447-50. PubMed ID: 17944704
[TBL] [Abstract][Full Text] [Related]
12. High prevalence of azole resistance in Aspergillus fumigatus isolates from high-risk patients.
Fuhren J; Voskuil WS; Boel CH; Haas PJ; Hagen F; Meis JF; Kusters JG
J Antimicrob Chemother; 2015 Oct; 70(10):2894-8. PubMed ID: 26163402
[TBL] [Abstract][Full Text] [Related]
13. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus.
Arikan S; Sancak B; Alp S; Hascelik G; McNicholas P
Med Mycol; 2008 Sep; 46(6):567-73. PubMed ID: 19180726
[TBL] [Abstract][Full Text] [Related]
14. Low prevalence of resistance to azoles in Aspergillus fumigatus in a French cohort of patients treated for haematological malignancies.
Alanio A; Sitterlé E; Liance M; Farrugia C; Foulet F; Botterel F; Hicheri Y; Cordonnier C; Costa JM; Bretagne S
J Antimicrob Chemother; 2011 Feb; 66(2):371-4. PubMed ID: 21131690
[TBL] [Abstract][Full Text] [Related]
15. Time-Kill Kinetics and In Vitro Antifungal Susceptibility of Non-fumigatus Aspergillus Species Isolated from Patients with Ocular Mycoses.
Öz Y; Özdemir HG; Gökbolat E; Kiraz N; Ilkit M; Seyedmousavi S
Mycopathologia; 2016 Apr; 181(3-4):225-33. PubMed ID: 26612621
[TBL] [Abstract][Full Text] [Related]
16. Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles.
van der Linden JW; Camps SM; Kampinga GA; Arends JP; Debets-Ossenkopp YJ; Haas PJ; Rijnders BJ; Kuijper EJ; van Tiel FH; Varga J; Karawajczyk A; Zoll J; Melchers WJ; Verweij PE
Clin Infect Dis; 2013 Aug; 57(4):513-20. PubMed ID: 23667263
[TBL] [Abstract][Full Text] [Related]
17. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
[TBL] [Abstract][Full Text] [Related]
18. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species.
Arikan S; Lozano-Chiu M; Paetznick V; Nangia S; Rex JH
J Clin Microbiol; 1999 Dec; 37(12):3946-51. PubMed ID: 10565912
[TBL] [Abstract][Full Text] [Related]
19. Susceptibility testing of sequential isolates of Aspergillus fumigatus recovered from treated patients.
Dannaoui E; Meletiadis J; Tortorano AM; Symoens F; Nolard N; Viviani MA; Piens MA; Lebeau B; Verweij PE; Grillot R; And The Ebga Network
J Med Microbiol; 2004 Feb; 53(Pt 2):129-134. PubMed ID: 14729934
[TBL] [Abstract][Full Text] [Related]
20. Multi-azole resistance in Aspergillus fumigatus.
Howard SJ; Webster I; Moore CB; Gardiner RE; Park S; Perlin DS; Denning DW
Int J Antimicrob Agents; 2006 Nov; 28(5):450-3. PubMed ID: 17034993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]